^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Valcyte (valganciclovir)

    i
    Other names: RS-079070194, RS-79070, TA 9070, RO1079070/194, RS079070194, RS79070, TA9070, R127, RG127, TA-9070, RG 127, RO 1079070/194, RS 079070194, RS 79070, RO-1079070/194
    Associations

    News

    Trials
    Company:
    Roche, Tanabe Pharma
    Drug class:
    Cytomegalovirus replication inhibitor
    Associations

    News

    Trials
    3d
    STACCATO I/II: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II (clinicaltrials.gov)
    P2, N=117, Not yet recruiting, University of California, San Francisco
    New P2 trial
    |
    Valcyte (valganciclovir)
    4d
    POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Duke University | Trial primary completion date: Sep 2026 --> Mar 2027
    Trial primary completion date
    |
    dexamethasone • metformin • Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kevzara (sarilumab) • Kineret (anakinra) • Orencia (abatacept) • Valcyte (valganciclovir) • aspirin
    9d
    De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients (clinicaltrials.gov)
    P3, N=30, Active, not recruiting, Virginia Commonwealth University | N=60 --> 30 | Trial primary completion date: Mar 2026 --> Sep 2026
    Enrollment change • Trial primary completion date
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    Valcyte (valganciclovir)
    9d
    KPoP: Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients (clinicaltrials.gov)
    P3, N=360, Recruiting, University of California, San Francisco | Trial primary completion date: Jan 2029 --> Nov 2030
    Trial primary completion date
    |
    Valcyte (valganciclovir)
    18d
    Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (clinicaltrials.gov)
    P2, N=28, Recruiting, The Methodist Hospital Research Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Valcyte (valganciclovir)
    25d
    Breakthrough CMV Lung Transplant -Multicentre (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, University of Alberta | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Valcyte (valganciclovir)
    28d
    GVO-1102: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Terminated, GenVivo, Inc. | Trial completion date: Mar 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Mar 2026; Sponsor strategic business decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    GEN2 • Valcyte (valganciclovir)
    2ms
    (PREVAIL-KT): Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (clinicaltrials.gov)
    P4, N=68, Active, not recruiting, University of Guadalajara
    New P4 trial
    |
    Valcyte (valganciclovir)
    2ms
    MARIBA-GITMO: A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance. (2025-521074-34-00)
    P1/2, N=81, Not yet recruiting, Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare
    New P1/2 trial
    |
    Valcyte (valganciclovir)
    2ms
    CLEAR-CMV: Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients (clinicaltrials.gov)
    P4, N=40, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Valcyte (valganciclovir)
    2ms
    Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma. (PubMed, Clin J Gastroenterol)
    Valganciclovir was initiated, and prednisolone was discontinued. Although irAE gastritis is a rare complication of ICI therapy, it should be considered in patients presenting with upper gastrointestinal symptoms during treatment. The management of irAE gastritis requires vigilance for opportunistic infections, timely histopathological evaluation, and careful differentiation from viral infections, especially in cases refractory to corticosteroids.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Valcyte (valganciclovir)
    2ms
    Unmasking Cytomegalovirus Colitis: A Case of Haemorrhagic Colitis in a Patient with Chronic Myeloid Leukaemia on Dasatinib. (PubMed, Eur J Case Rep Intern Med)
    In immunosuppressed patients being treated with dasatinib, haemorrhagic colitis can mask an underlying infection.Tissue biopsy constitutes a key tool for promptly diagnosing cytomegalovirus colitis, enabling clinicians to start treatment early and thus prevent adverse outcomes.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    dasatinib • Valcyte (valganciclovir)